BioNTech Signs an Exclusive Worldwide License and Collaboration Agreement with OncoC4 to Co-Develop and Commercialize ONC-392
- OncoC4 will receive $200M up front & eligible for development, regulatory & commercial milestones along with royalties & the transaction is expected to close in H1’23. BioNTech to get exclusive commercialization right globally for ONC-392 with the participation of OncoC4 in certain markets
- Both companies will jointly develop ONC-392 (anti-CTLA-4 mAb candidate) as monotx. & in combination with anti-PD-(L)-1 Abs for solid tumors & share equal development costs. BioNTech also plans to combine ONC-392 with oncology product candidates to evaluate complementary modes of action to increase therapeutic effect & unlock larger patient populations
- The P-I/II trial of ONC-392 was presented at SITC in 2022 and 2021 while the P-III trial is expected to initiate in 2023
Ref: Biontech | Image: Biontech
Related News:- Pfizer and BioNTech Receive the US FDA’s EUA for Omicron BA.4/BA.5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
